Media stories about Stemline Therapeutics (NASDAQ:STML) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Stemline Therapeutics earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.6460062344768 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Several equities analysts have recently weighed in on the company. BidaskClub upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 6th. Wedbush boosted their target price on Stemline Therapeutics from $20.00 to $22.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 29th. ValuEngine upgraded Stemline Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 2nd. Finally, Roth Capital started coverage on Stemline Therapeutics in a research report on Tuesday, June 12th. They set a “buy” rating and a $30.00 target price for the company. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $30.00.

Stemline Therapeutics stock opened at $15.85 on Monday. Stemline Therapeutics has a 52 week low of $9.25 and a 52 week high of $20.55. The stock has a market cap of $490.95 million, a P/E ratio of -5.39 and a beta of 0.30.

Stemline Therapeutics (NASDAQ:STML) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.02). The company had revenue of $0.50 million during the quarter. equities research analysts predict that Stemline Therapeutics will post -2.78 EPS for the current year.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Further Reading: What do investors mean by earnings per share?

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with's FREE daily email newsletter.